Marco Bonavia
Genoa, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: March 21, 2026
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus.
Journal: The journal of allergy and clinical immunology. In practice
Published: May 17, 2023
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.
Journal: Biomedicines
Published: May 11, 2023
Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up.
Journal: International journal of cardiology
Published: March 19, 2021
Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series.
Journal: Journal of asthma and allergy
Published: December 11, 2020
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI).
Journal: The World Allergy Organization journal
Published: April 16, 2020
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis.
Journal: Respiratory medicine
Published: March 20, 2020
The prevalence of sleep impairments and predictors of sleep quality among patients with asthma.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: January 07, 2020
The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life.
Journal: Allergy
Published: September 24, 2019
One year of mepolizumab. Efficacy and safety in real-life in Italy.
Journal: Pulmonary pharmacology & therapeutics
Published: May 11, 2019
Last Updated: 09/26/2026